Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efepoetin alfa
- Development stage
- Phase 2
- Lead developer
- Genexine
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Efepoetin alfa (GX-E2) is a long-acting recombinant erythropoietin fusion protein developed using Genexine's proprietary hyFc platform technology. It consists of human erythropoietin fused to the Fc region of an antibody to extend its half-life and allow for less frequent dosing. The drug acts as an erythropoiesis stimulant by binding and activating the erythropoietin receptor to promote red blood cell production. Its primary indication is the treatment of anemia associated with chronic kidney disease (CKD), including in patients on dialysis and those not on dialysis. Efepoetin alfa has been co-developed by Genexine and Green Cross (now CG Biopharma), with additional development partnerships for commercialization in China through Shanghai Fosun Pharmaceutical subsidiaries[1][3][6][7].
- Brand names
- Efesa
- Other names
- Ephepoetin AlphaLong-acting EPORecombinant erythropoietin long-actingHyPoietin
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on efepoetin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efepoetin alfa.